Login to Your Account

'XLHED' Marks the Spot in $18M Edimer Round

By Marie Powers
Staff Writer

Tuesday, July 30, 2013
Edimer Pharmaceuticals Inc. showed that ultra-rare indications continue to resonate with investors, pulling in $18 million in a Series B to fund trials of EDI200, an ectodysplasin-A (EDA-A1) replacement protein that represents the first in a class of molecules rationally designed to correct a specific developmental disorder.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription